Ultragenyx Faces Lawsuit Over Allegedly Misleading Setrusumab Trial Statements

Ultragenyx Faces Class Action Lawsuit Over Misleading Statements Regarding Setrusumab Trials

Ultragenyx Pharmaceutical Inc. is currently embroiled in a class action lawsuit initiated by Robbins Geller Rudman & Dowd LLP, which targets purchasers of the company's common stock from August 3, 2023, to December 26, 2025. The lawsuit, titled Bailey v. Ultragenyx Pharmaceutical Inc., alleges violations of the Securities Exchange Act of 1934, focusing primarily on misleading statements made about the Phase III Orbit study of setrusumab, a treatment aimed at Osteogenesis Imperfecta (OI). The lawsuit asserts that the company's executives provided overly optimistic information regarding the reliability and potential effectiveness of the study, which has since been called into question due to failure to meet its primary endpoints in subsequent assessments.

The allegations highlight critical moments in the timeline of the Orbit study. As per the claims, Ultragenyx downplayed the risks associated with the treatment, leading to an undisclosed gap between the company's projections and the actual clinical outcomes. This gap became evident when Ultragenyx announced on July 9, 2025, that the Orbit study had not reached statistical significance during its second interim analysis. Following this announcement, the company's stock price witnessed a significant decline, dropping over 25%. The situation worsened on December 29, 2025, when the company confirmed that both the Phase III Orbit and Cosmic studies had not succeeded in achieving their primary endpoints, reinforcing the concerns raised by the class action about the company's earlier communications and their impacts on investors.

As the class action progresses, investors who believe they suffered financial losses during the outlined timeframe are eligible to seek lead plaintiff status, with the deadline set for April 6, 2026. Interested parties can make claims through a designated link from Robbins Geller or reach out to attorney J.C. Sanchez directly. This litigation comes at a critical time for Ultragenyx, as the company may need to reevaluate its communications strategy and trial reporting protocols in light of the heightened scrutiny over its clinical data disclosures.

In the evolving landscape of biopharmaceuticals, the trust between companies and their investors significantly impacts market confidence and investment strategies. Ultragenyx's situation serves as a reminder of the complexities surrounding clinical trial reporting and the potential repercussions when the perceived efficacy of a treatment fails to align with actual outcomes. Additionally, the lawsuit underscores the importance of transparency in the biopharma sector, where misleading assertions can have severe consequences for stakeholders. As Ultragenyx navigates this legal challenge, it could also potentially redefine its strategies for handling clinical data and investor communications moving forward.